- Home
- CANF
as 11-20-2024 4:00pm EST
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
Upcoming Earnings Alert:
Get ready for potential market movements as Can-Fite Biopharma Ltd Sponsored ADR (Israel) CANF prepares to release earnings report on 26 Nov 2024.
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 14.4M | IPO Year: | N/A |
| Target Price: | $14.00 | AVG Volume (30 days): | 63.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.87 - $4.69 | Next Earning Date: | 11-26-2024 |
| Revenue: | $667,000 | Revenue Growth: | -15.89% |
| Revenue Growth (this year): | 409.56% | Revenue Growth (next year): | N/A |
Latest Can-Fite Biopharma Ltd Sponsored ADR (Israel) News
CANF Breaking Stock News: Dive into CANF Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer
GlobeNewswire
10 days ago
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
TipRanks
16 days ago
Can-Fite BioPharma Secures Australian Patent for Obesity Drug
GlobeNewswire
17 days ago
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
MT Newswires
a month ago
Can-Fite BioPharma's Partner Reports Positive Study Results of Piclidenoson in Dogs With Osteoarthritis
GlobeNewswire
a month ago
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
MT Newswires
a month ago
Can-Fite BioPharma Says Its Pancreatic Cancer Drug Candidate Receives US FDA Orphan Drug Designation
GlobeNewswire
a month ago
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Compare CANF vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.